How is busulfan administered?
Busulfan Injection 0.8 mg per kg (ideal body weight or actual body weight, whichever is lower) intravenously via a central venous catheter as a two-hour infusion every six hours for four consecutive days for a total of 16 doses (Days -7, -6, -5 and -4).
What is the mechanism of action of busulfan?
Specifically, its mechanism of action through alkylation produces guanine-adenine intrastrand crosslinks. These crosslinks occur through a SN2 reaction guanine N7 nucleophilically attacks the carbon adjacent to the mesylate leaving group.
What is busulfan used for?
Descriptions. Busulfan injection is used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for treatment of chronic myelogenous leukemia. Busulfan belongs to the group of medicines known as alkylating agents.
Is busulfan a chemo drug?
Busulfan is a chemotherapy drug. It is a treatment for chronic myeloid leukaemia (CML) and some types of blood cancers called myelodysplastic syndromes (MDS). Or you might have it as a treatment before a stem cell or bone marrow transplant.
How do you dilute busulfan?
Dilute busulfan to 3 mg/ml with sterile phosphate buffered saline (PBS). NOTE: It is important to make a fresh dilution of busulfan just prior to use each day of injection. Administer 20 mg/kg of diluted busulfan to recipient mice via IP injection daily.
What is the drug classification for busulfan?
Busulfan is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body.
What are the contraindications of busulfan?
Who should not take BUSULFAN?
- a bad infection.
- low amount of magnesium in the blood.
- low amount of potassium in the blood.
- significantly decreased activity of the bone marrow.
- anemia.
- decreased blood platelets.
- low levels of a type of white blood cell called neutrophils.
- hepatic veno-occlusive disease, a type of liver disease.
Is busulfan still used?
Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug’s relative low cost.
What is busulfan lung damage?
Busulfan can cause interstitial fibrosing lung disease (“busulfan lung”) with an estimated incidence of 6% [5]. It begins gradually, causes dyspnea and cough, and is often accompanied by skin pigmentation. It usually occurs after prolonged treatment (on average 41 months, cumulative dose 2900 mg).
Is busulfan carcinogenic?
Busulfan is a direct-acting alkylating agent that is carcinogenic via a genotoxic mechanism. There is sufficient evidence in humans for the carcinogenicity of busulfan. Busulfan causes acute myeloid leukaemia. There is limited evidence in experimental animals for the carcinogenicity of busulfan.
Is busulfan toxic?
Busulfan was the first cytotoxic drug reportedly associated with pulmonary toxicity [1]. The reported patterns of pulmonary toxicity include acute lung injury, chronic interstitial fibrosis, and alveolar hemorrhage.
How is busilvex administered?
Busilvex is administered prior to the haematopoietic progenitor cell transplantation (HPCT). The recommended dose and schedule of administration is: – 0.8 mg/kg body weight (BW) of busulfan as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses,
Is busilvex authorised in the European Union?
This medicine is authorised for use in the European Union. This is a summary of the European public assessment report (EPAR) for Busilvex.
What are the side effects of busilvex?
Apart from the decrease in blood cell counts, which is the intended effect of the medicine, the most serious side effects of Busilvex are infection, liver disorders including blocking of a liver vein, graft versus host disease (when the transplanted cells attack the body) and respiratory (lung) disorders.
What is the pharmacokinetics of busilvex (busulfan)?
The pharmacokinetics of Busilvex has been investigated. The information presented on biotransformation and elimination is based on oral busulfan. The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2-hour intravenous infusion for a total of 16 doses over four days.